Can Wegovy be microdosed, and does it actually work?

Step 1: understand what the licensed schedule is designed to do

The Wegovy titration ladder exists for a reason. You start on 0.25 mg weekly (a dose the manufacturers describe as a tolerability step, not a weight-loss dose) before moving through 0.5 mg, 1.0 mg and 1.7 mg toward the 2.4 mg maintenance level, with roughly four weeks at each rung. The MHRA approved this schedule because the phase 3 STEP 1 trial, published in the New England Journal of Medicine, tested 2.4 mg as the therapeutic endpoint: participants lost an average of around 15% of body weight over 68 weeks at that dose. The starter doses exist to let the gut adapt to semaglutide's effect on gastric emptying, not to deliver results in their own right. Staying at 0.25 mg or 0.5 mg for months on end is, in clinical terms, an extended tolerability phase, which is not the same thing as a deliberate microdosing strategy, but is sometimes conflated with one online.

The Wegovy treatment page sets out the approved UK pathway, including the newer 7.2 mg pen approved by the MHRA in April 2026, if you want a grounding in where the licensed schedule currently sits.

Step 2: see what microdosing actually means in practice

When people ask whether Wegovy can be microdosed, they usually mean one of three things: taking a smaller volume from each pen than the full weekly dose, stretching injections to every two or three weeks instead of weekly, or deliberately staying on a sub-maintenance dose long-term. None of these approaches has been tested in a randomised controlled trial. The concern with the first approach is that Wegovy pens are pre-set single-use devices; they are not designed to be dialled down, and any attempt to extract a partial dose risks inaccurate dosing and potential pen misuse. The second and third approaches may simply mean spending months at a dose that does not deliver the appetite-regulation and gastric-emptying effects the medicine is licensed to produce.

If your interest in microdosing Wegovy is driven by concerns about tolerability, that is a legitimate clinical conversation, but the evidence-based answer is usually a slower titration pace within the licensed structure, not a permanent fraction of the maintenance dose. There is a meaningful difference between the two, and it matters for whether you will see results.

Step 3: know what the evidence does (and does not) support

NICE's appraisal of semaglutide for weight management, published as TA875, is built on the trial data from the STEP programme and recommends stopping treatment if a patient has not lost at least 5% of body weight after six months on the maintenance dose. That threshold implies reaching maintenance. If a patient remains on a sub-therapeutic amount indefinitely, the clinical review framework that NICE describes cannot be applied properly, because the medicine has never been given the conditions under which it is known to work.

That does not mean every person on Wegovy must push to 2.4 mg regardless of how they feel. A prescriber may legitimately keep someone at a lower dose if that is the highest they tolerate, the distinction is that this is a clinical decision based on a full picture, not a self-directed strategy. The purported benefits of microdosing semaglutide are discussed in more detail if you want to explore the anecdotal claims alongside what clinical evidence does and does not back up.

Step 4: what to actually do if standard dosing feels too much

The most practical step is to tell your prescriber exactly what is happening. Nausea, disrupted digestion and fatigue are common in the first weeks on a new or increased dose; the NHS medicines page for semaglutide confirms that these effects are typically most noticeable after starting or after a dose increase, and tend to settle within days to a couple of weeks. A clinician can slow the titration schedule (spending eight weeks at a dose rather than four, for example) which is within the spirit of the licensed pathway and keeps the long-term trajectory intact.

For anyone weighing up the broader cost and commitment involved before making any changes, the Wegovy price comparison page covers what private treatment typically costs across different providers, so the financial side of a longer titration timeline is clear. Slowing the pace adds months but does not change the overall eligibility or the clinical goal.

If you have tried the licensed doses and find yourself wondering whether microdosing semaglutide is the right path for you, speaking to a prescriber about your specific situation is the right starting point. Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber on the same day, a real clinician assessing your case, not an automated system working through a form.